Fig 2: Difference analysis and prognostic analysis of hub genes (ANGPT2, VCAN, MS4A4A, and FOS). (a–d) Prognostic analysis of hub genes (ANGPT2, VCAN, MS4A4A, and FOS) in patients with esophageal cancer. (e) Intersection between genes in important modules of WGCNA and differential genes in normal and tumor tissues. (f) Difference analysis of hub genes (ANGPT2, VCAN, MS4A4A, and FOS) between normal tissues and tumor tissues.

Fig 3: DEGs and cell subsets identification in esophageal cancer with single cell analysis. (a) High quality cell filtration. Cells were filtrated with the number of genes in cells nFeature >200 and =7000; the proportion of mitochondrial genes in cells (percent.mt< 20). (b) Filtration of top 2000 highly variable genes (HVGs). (c) Sample pooling and batch correction. (d) The PCA cluster of each sample. (e) The exhibition of cell subsets. (f) The expression of VCAN in tumor tissue and adjacent tissue. (g) The expression of ANGPT2 in tumor tissue and adjacent tissue. (h) The expression of MS4A4A in tumor tissue and adjacent tissue. (i) The expression of FOS in tumor tissue and adjacent tissue. (j) The expression of different immune cell types in tumor tissue and adjacent tissue. (k) The bubble plot of marker gene expression in different cell types identification.